007 2 1 200x 55

1FW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 18, 2004

Signature: (Nabeela R. McMillian)

Docket No.: 30610/39383

(PATENT)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Zankel et al.

Application No.: 10/600,862

Filed: June 20, 2003

Art Unit: 1646

For: USE OF CHAPERONE RECEPTOR

ASSOCIATED PROTEIN (RAP) FOR THE

**DELIVERY OF THERAPEUTIC** 

COMPOUNDS TO THE BRAIN AND OTHER

**TISSUES** 

Examiner: Not Yet Assigned

# REQUEST FOR CORRECTED FILING RECEIPT

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has an error in:

Domestic Priority data as claimed by applicant

Please delete "This application is a CIP of 10/206,446 07/26/2002."

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Application No.: 10/600,862 Docket No.: 30610/39383

Please note that an amendment to delete claim for priority was previously filed on November 26, 2003 in the subject matter, a copy of which is attached for your reference. Therefore, Applicants respectfully request that the deletion of the priority claim be reflected in a corrected Filing Receipt and any publication of the application take this amendment into account.

Dated: October 18, 2004

Respectfully submitted

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

**Sears Tower** 

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1459 Alexandra, Virginia 22313-1450 www.uspto.gov

FILING OR 371 ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS APPL NO. (c) DATE 10/600.862 06/20/2003 1646 566 30610/39383 20 13 6

**CONFIRMATION NO. 8574** 

Nabeela R. McMillian MARSHALL, GERSTEIN & BORUN LLP Sears Tower 233 S. Wacker Drive, Suite 6300 Chicago, IL 60606-6357

RECEIVED

**UPDATED FILING RECEIPT** 

\*OC000000013858870\*

SFP 2 8 2004

Date Mailed: 09/22/2004

## MARSHALL GERSTEIN

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Todd Zankel, San Francisco, CA; Christopher M. Starr, Sonoma, CA; Reinhard Gabathuler, San Rafael, CA;

#### **Assignment For Published Patent Application**

BioMarin Pharmaceutical Inc., Novato, CA

Power of Attorney: The patent practitioners associated with Customer Number <u>04743</u>.

## Domestic Priority data as claimed by applicant

This application is a CIP of 10/206,446 07/26/2002

#### Foreign Applications

If Required, Foreign Filing License Granted: 11/05/2003

The number of your priority application, to be used for filing abroad under the Paris Convention is, US10/600.862

Projected Publication Date: 12/30/2004

Non-Publication Request: No

BEST AVAILABLE COPY

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues

**Preliminary Class** 

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).